Article

CAR T-Cell Therapy Offers Hope in DLBCL

CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.

Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann, M.D., professor at the University Hospital of Cologne in Germany.

The phase 2 trial is investigating the CAR-T cell therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory DLBCL. Borchmann explained that at the median follow-up of 14 months, the researchers are still seeing a high amount of patients who are responding to treatment. While longer observation is needed, he said that the findings from this study are generating hope that more patients with DLBCL can obtain and remain in remission.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Image of Doctor.
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Doug
Image of doctor.
Image of Dr. Kelly
Image of Dr. Boffa.
Immune Therapy Expands Melanoma Treatment to More Patients
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
Related Content